Clinical Pathway Builder - Low-Risk Primary Myelofibrosis

Submitted by onc_editor on Fri, 02/09/2018 - 19:54

Welcome to Journal of Clinical Pathway’s new clinical pathway interactive builder. This new interactive feature allows you to review the treatment options for low-risk primary myelofibrosis, share your approach to determining the highest value treatment, and help to build a consensus clinical pathway for this disease.

Next: Design the Pathway

 

The National Comprehensive Cancer Network (NCCN) provides evidence blocks as visual representations of five key measures that provide important information about specific recommendations contained in the treatment guidelines. The measures included in these blocks are efficacy of regiment/agent, safety of regiment/agent, quality of evidence, consistency of evidence, and affordability of regiment/agent. Each measure is scored on a 1-5 scale, with 5 representing the highest degree and 1 representing the lowest degree.

For the treatment of low-risk primary myelofibrosis, the NCCN recommends any of five regimens: hydroxyurea, interferon alpha-2b, peginterferon alpha-2a, peginterferon alpha-2b, and ruxolitinib. Below are the evidence blocks for each of these regimens:

Hydroxyurea
2                      Efficacy
4                      Safety
2                      Quality of evidence
3                      Consistency of evidence
4                      Affordability
 

Interferon alpha 2-b
2
3
2
2
2
 

Peginterferon alpha-2a
3
3
2
2
2


Peginterferon alpha-2b
3
3
2
2
2
 

Ruxolitinib
3
4
3
3
1